Literature DB >> 22139552

Usefulness of 18F-FDG uptake with clinicopathologic and immunohistochemical prognostic factors in breast cancer.

Bom Sahn Kim1, Sun Hee Sung.   

Abstract

INTRODUCTION: The aim of this study was to analyze the clinical significance of maxSUV with clinicopathologic and immunohistochemical prognostic factors in patients with primary breast cancer.
METHODS: Ninety-one women (48.5 ± 11.2 years of age) with breast cancer who underwent (18)F-FDG PET (PET) before surgery were recruited. All of the breast cancers were invasive ductal carcinomas and ≥1 cm in size to exclude a partial volume effect. The maxSUV of breast cancers was compared with histopathologic and immunohistochemical findings. Additionally, the ability of PET to discriminate axillary nodal status (ANS) and correlation between ANS and tumor characteristics were evaluated.
RESULTS: A high maxSUV of breast cancer was significantly correlated with the following poor prognosis factors: tumor invasiveness >2 cm (2.9 vs. 5.4; p < 0.001); high score of nuclear (3.5 vs. 5.3; p = 0.008) or histologic grade (3.3 vs. 5.5; p < 0.001); MIB-1 ≥10% (3.0 vs. 4.9; p < 0.002); ER-negativity (4.8 vs. 3.8; p = 0.019); PR-negativity (5.0 vs. 3.6; p = 0.029); and triple negativity (ER-, PR-, and c-erbB-2-negative; 5.3 vs. 3.8; p < 0.016). MaxSUV was not affected by menopausal status, ANS, lymphovascular invasion, including CD34 and D2-40 (LVIs), p53, and c-erbB-2 status. Additionally, the sensitivity and specificity of PET for discriminating ANS were 51.1 and 97.8%, respectively. ANS was correlated with tumor invasiveness >2 cm (p = 0.046), LVIs (all of variables; p < 0.001), and triple negativity (p = 0.049).
CONCLUSIONS: A high FDG uptake of breast tumor is correlated with several poor prognosis factors, such as tumor invasiveness >2 cm, higher tumor grade, higher MIB-1, hormonal receptor negativity, and triple negativity. However, PET has a limited value in discriminating axillary lymph nodes. Pre-operative PET is a useful modality to predict biologic poor prognosis factors which could affect adjunctive therapy of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22139552     DOI: 10.1007/s12149-011-0556-1

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  14 in total

1.  PET/CT and breast cancer subtypes.

Authors:  Laura Gilardi; Marco Colleoni; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-09       Impact factor: 9.236

2.  Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT.

Authors:  Hai-Jeon Yoon; Keon Wook Kang; In Kook Chun; Nariya Cho; Seock-Ah Im; Sunjoo Jeong; Song Lee; Kyeong Cheon Jung; Yun-Sang Lee; Jae Min Jeong; Dong Soo Lee; June-Key Chung; Woo Kyung Moon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-03-21       Impact factor: 9.236

3.  Intratumoral metabolic heterogeneity predicts invasive components in breast ductal carcinoma in situ.

Authors:  Hai-Jeon Yoon; Yemi Kim; Bom Sahn Kim
Journal:  Eur Radiol       Date:  2015-06-11       Impact factor: 5.315

4.  Preoperative FDG PET/CT in breast cancer patients: where are we going?

Authors:  Laura Gilardi; Concetta De Cicco; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11       Impact factor: 9.236

5.  Relationship between reticuloendothelial systems' FDG uptake level and clinicopathological features in patient with invasive ductal breast cancer.

Authors:  Ertan Şahin; Umut Elboğa
Journal:  Radiol Med       Date:  2017-06-09       Impact factor: 3.469

6.  Assessment of cell proliferation in renal cell carcinoma using dual-phase 18F-fluorodeoxyglucose PET/CT.

Authors:  Rei Onishi; Masanori Noguchi; Hayato Kaida; Fukuko Moriya; Katsuaki Chikui; Seiji Kurata; Akihiko Kawahara; Masayoshi Kage; Masatoshi Ishibashi; Kei Matsuoka
Journal:  Oncol Lett       Date:  2015-06-11       Impact factor: 2.967

7.  Prognostic Significance of Metabolic Tumor Volume Measured by (18)F-FDG PET/CT in Operable Primary Breast Cancer.

Authors:  Jahae Kim; Su Woong Yoo; Sae-Ryung Kang; Sang-Geon Cho; Jong-Ryool Oh; Ari Chong; Jung-Joon Min; Hee-Seung Bom; Jung-Han Yoon; Ho-Chun Song
Journal:  Nucl Med Mol Imaging       Date:  2012-08-25

8.  Correlation of Primary Tumor FDG Uptake with Clinicopathologic Prognostic Factors in Invasive Ductal Carcinoma of the Breast.

Authors:  I Jo; Seok Kil Zeon; Sung Hoon Kim; Hae Won Kim; Sun Hee Kang; Sun Young Kwon; Su Jin Kim
Journal:  Nucl Med Mol Imaging       Date:  2014-10-02

Review 9.  Power of two: combination of therapeutic approaches involving glucose transporter (GLUT) inhibitors to combat cancer.

Authors:  Kalpana Tilekar; Neha Upadhyay; Cristina V Iancu; Vadim Pokrovsky; Jun-Yong Choe; C S Ramaa
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-10-21       Impact factor: 10.680

10.  Relationship between 18-FDG-PET/CT and Clinicopathological Features and Pathological Responses in Patients with Locally Advanced Breast Cancers.

Authors:  Nilgun Yildirim; Melih Simsek; Mehmet Naci Aldemir; Mehmet Bilici; Salim Basol Tekin
Journal:  Eurasian J Med       Date:  2019-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.